Ian Edward Alexander

Ian Edward Alexander

Auto-generated profile, based on publicly available information

Ian Edward Alexander

Sydney Children's Hospitals Network and Children's Medical Research Institute

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2003 in Science
Verified
Journal Article
Closed access
PDF file
SHS. Hacein-Bey-Abina
S. Hacein-Bey-Abina
CKC. Von Kalle
C. Von Kalle
MSM. Schmidt
M. Schmidt
MMM. P. McCormack
M. P. McCormack
NWN. Wulffraat
N. Wulffraat
MCM. Cavazzana-Calvo
M. Cavazzana-Calvo
We have previously shown correction of X-linked severe combined immunodeficiency [SCID-X1, also known as γ chain (γc) deficiency] in 9 out of 10 patients by retrovirus-mediated γc gene transfer into autologous CD34 bone marrow cells. However, almost 3 years after gene therapy, uncontrolled exponential clonal proliferation of mature T cells (with γδ+ or αβ+ T cell receptors) has occurred in the two youngest patients. Both patients' clones showed retrovirus vector integration in proximity to the LMO2 proto-oncogene promoter, leading to aberrant transcription and expression of LMO2 . Thus, retrovirus vector insertion can trigger deregulated premalignant cell proliferation with unexpected frequency, most likely driven by retrovirus enhancer activity on the LMO2 gene promoter.

19 April 2018 in The Journal of Gene Medicine
Verified
Journal Article
Closed access
PDF file
SGSamantha Ginn
Samantha Ginn
AAAnais K. Amaya
Anais K. Amaya
IAIan E. Alexander
Ian E. Alexander
MEMichael Edelstein
Michael Edelstein
MAMohammad R. Abedi
Mohammad R. Abedi

27 February 2013 in The Journal of Gene Medicine
Verified
Journal Article
Closed access
PDF file
SGSamantha L. Ginn
Samantha L. Ginn
IAIan E. Alexander
Ian E. Alexander
MEMichael L. Edelstein
Michael L. Edelstein
MAMohammad R. Abedi
Mohammad R. Abedi
JWJo Wixon
Jo Wixon

25 December 2013 in Nature
Verified
Journal Article
Open access
PDF file
LLLeszek Lisowski
Leszek Lisowski
ADAllison P. Dane
Allison P. Dane
KCKirk Chu
Kirk Chu
YZYue Zhang
Yue Zhang
SCSharon C. Cunningham
Sharon C. Cunningham
MKMark A. Kay
Mark A. Kay
Chimaeric human–murine adeno-associated virus (AAV) capsids are described that transduce human primary hepatocytes more efficiently than currently used AAV vectors; the novel vectors may be good clinical candidates. One of the most promising gene-therapy vectors currently in clinical trials is the rAAV8 (recombinant adeno-associated viral serotype 8) virus. Yet the performance of this, and some other AAV vectors, often fails to live up to expectations raised by the results of animal studies. Here Mark Kay et al. use a mouse model with a chimaeric murine/human liver to compare rAAV transduction efficiency in human and mouse cells. They find that the rAAV2 vector transduces both species equally well, but that AAV8 is about 20-fold less efficient at transducing human cells than mouse cells. The data correlate well with clinical data and may go some way towards explaining why rAAV8 underperforms in human trials. The authors suggest that the use of a human primary cell xenotransplant model may more accurately predict potential transduction efficiency in humans than the commonly used mouse and non-human primate models. Recombinant adeno-associated viral (rAAV) vectors have shown early promise in clinical trials1,2,3. The therapeutic transgene cassette can be packaged in different AAV capsid pseudotypes, each having a unique transduction profile. At present, rAAV capsid serotype selection for a specific clinical trial is based on effectiveness in animal models. However, preclinical animal studies are not always predictive of human outcome4,5,6,7,8. Here, in an attempt to further our understanding of these discrepancies, we used a chimaeric human–murine liver model to compare directly the relative efficiency of rAAV transduction in human versus mouse hepatocytes in vivo. As predicted from preclinical and clinical studies4,5,8, rAAV2 vectors functionally transduced mouse and human hepatocytes at equivalent but relatively low levels. However, rAAV8 vectors, which are very effective in many animal models, transduced human hepatocytes rather poorly—approximately 20 times less efficiently than mouse hepatocytes. In light of the limitations of the rAAV vectors currently used in clinical studies, we used the same murine chimaeric liver model to perform serial selection using a human-specific replication-competent viral library composed of DNA-shuffled AAV capsids. One chimaeric capsid composed of five different parental AAV capsids was found to transduce human primary hepatocytes at high efficiency in vitro and in vivo, and provided species-selected transduction in primary liver, cultured cells and a hepatocellular carcinoma xenograft model. This vector is an ideal clinical candidate and a reagent for gene modification of human xenotransplants in mouse models of human diseases. More importantly, our results suggest that humanized murine models may represent a more precise approach for both selecting and evaluating clinically relevant rAAV serotypes for gene therapeutic applications.

1 January 2014 in Cell Stem Cell
Verified
Journal Article
Closed access
YKYoji Kojima
Yoji Kojima
KKKeren Kaufman-Francis
Keren Kaufman-Francis
JSJoshua B. Studdert
Joshua B. Studdert
KSKirsten A. Steiner
Kirsten A. Steiner
MPMelinda D. Power
Melinda D. Power
PTPatrick Tam
Patrick Tam

1 February 2005 in Circulation
Verified
Journal Article
Closed access
PDF file
EKEddy Kizana
Eddy Kizana
SGSamantha L. Ginn
Samantha L. Ginn
DADavid G. Allen
David G. Allen
DRDavid L. Ross
David L. Ross
IAIan E. Alexander
Ian E. Alexander
Background— Cardiac conduction occurs in an electrical syncytium of excitable cells connected by gap junctions. Disruption of these electrophysiological properties causes conduction slowing or block. Depending on the location of affected cells within the heart, this has the potential to result in clinical syndromes such as atrioventricular block. With a view to developing gene therapy strategies for repairing cardiac conduction defects, we sought to establish whether the phenotype of fibroblasts can be modified by gene transfer to produce cells capable of electrical excitation and coupling. Methods and Results— High-titer lentiviral vectors encoding MyoD, a myogenic transcription factor, and connexin43, a gap junction protein, were produced by established methods. Human dermal fibroblasts (HDFs) were efficiently (>80%) transduced at a multiplicity of infection of 50. HDFs transduced with the MyoD-encoding vector underwent myogenic conversion, as evidenced by myotube formation and detection of muscle-specific proteins. Importantly, calcium transients indicative of membrane excitability were observed in MyoD-induced myotubes after loading with a calcium-sensitive dye and electrical stimulation. Transients from adjacent myotubes displayed different excitation thresholds, indicating an absence of coupling between cells, consistent with skeletal muscle biology. In contrast, simultaneous transduction of HDFs with MyoD and connexin43-encoding vectors resulted in the appearance of transients in adjacent myotubes with identical thresholds, indicative of electrical coupling. Notably, dye transfer studies confirmed gap junctional intercellular communication. Conclusions— Fibroblasts can be genetically modified to produce excitable cells capable of electrical coupling. These observations strengthen the prospect of developing gene-based strategies for repairing cardiac conduction defects.